Personal Genomics Reports: 5 Criteria to Trust or Skip Claims

This guide provides five binary criteria to determine whether to trust or skip a 2026 personal genomics report.

A report is trustworthy only when every health or trait claim names an analytical-validity study, a clinical-validity study matched to the buyer’s ancestry group, and a guideline-backed action; missing any one means skip.

How a 5-Point Validity Score Works

A 5-point validity score is a pass-fail gate, not a percentage. Five criteria, each scored 1 or 0, and the trust cutoff is 5/5 — every criterion at 1. A 4/5 report is not "almost trustworthy"; it is a skip, because each criterion guards a different failure mode, and one gap can undo the single claim you care about most.

C1, analytical validity, scores 1 only when the report names the assay that called the variant, names the lab that ran it, and points to a validation study showing the variant call itself is accurate. Verify any certification or accreditation claim independently with the named lab or authority. Accuracy language without a named study scores 0.

C2, clinical validity, scores 1 only when a named study links that variant to the stated condition in the buyer's own stated ancestry group. A variant documented only in European-ancestry cohorts earns 0 for a buyer who states Nigerian or Korean ancestry; associations can fail to transfer across groups, so a mismatched study is treated as no study at all.

C3, actionability, scores 1 only when the report cites a guideline-backed action — a screening step, a risk-reduction measure, a referral — or explicitly states that no action is indicated. The no-action statement counts as a pass because it stops a well-validated result from being misread as an alarm. Vague advice with no guideline anchor scores 0.

C4 scores 1 only when effect size or penetrance is stated for the claim: how large the increase is, or how often carriers actually develop the condition. "Raises risk" with no number, or a relative risk with no absolute baseline, scores 0. C5 scores 1 only when the report states that raw data can be exported in a standard, reusable format and documents assay provenance — the platform, version, and reference panel behind each call. A polished summary with no export path and no provenance line scores 0, because the buyer cannot verify or reuse the underlying data.

To apply the score, run the five questions in order — which assay and lab, validated how; which study, in which ancestry; which guideline action or explicit no-action; what effect size; what export — and count yeses. Five yeses clears the cutoff; any no, or any "not stated," is a skip regardless of how polished the report looks or how many other claims it gets right.

Evidence to Demand Before You Trust

This section alone requires a PMID or DOI plus ClinVar concordance and ancestry-matched replication for each claim. Before trusting any health or trait claim in a 2026 personal-genomics report, demand a citation chain that can be checked line by line. If a claim cannot show a PubMed PMID or DOI, ClinVar concordance, and ancestry-matched replication, treat it as unverified.

Build a five-column convergence table for every claim. The columns are claim, PubMed PMID or DOI, ClinVar review status, lab and assay match, and ancestry match. All five must point to the same variant and the same effect direction. A citation to a different variant, a different assay, or an opposite effect direction breaks convergence even if each source looks credible on its own.

For each health claim, require one PubMed-indexed association study and one independent replication. The first study establishes the association; the replication tests whether it survives a separate sample and analysis. If no PMID or DOI is shown, set C2 to 0 and stop scoring that claim. Do not substitute a company blog post, a preprint without a stable identifier, or an internal white paper for the PubMed-indexed study.

For each variant, check ClinVar for interpreted clinical significance and review status. Compare the company’s wording with the ClinVar record for the same variant. If the company’s interpretation conflicts with ClinVar’s interpreted significance or review status, require a documented explanation before the claim can count as clinically valid; otherwise leave C2 at 0 for that claim.

Ancestry match is not a footnote. The replication must include the buyer’s ancestry group, or the report must identify a source-supported basis for applying the finding to that group. Lab and assay match means the cited evidence should use the same variant and a comparable measurement approach, not a proxy marker or a different technology. When any of the five columns fails, the claim fails the evidence test even if the report scores well elsewhere.

Keep the evidence check separate from the action check. A claim can have a PMID, ClinVar concordance, and ancestry-matched replication and still lack a guideline-backed action; in that case the report may be useful for research but not for a trust decision. Score the evidence columns first, then apply the action criterion without upgrading a claim because its citation chain is strong.

Report Options: Trust, Research, Skip

When you evaluate a 2026 personal-genomics report, sort it into one of three postures—Trust, Research-only, or Skip—based on its five-criterion score. This comparison names the winner clearly: only a Trust report earns use in a health decision, while the other two postures serve narrower purposes or no purpose at all.

A Trust report is the explicit winner. At 5/5, it is the only posture that meets the standard set by the thesis: every health or trait claim is supported by the required evidence and tied to a guideline-backed action. If a report reaches this level, you can treat its claims as decision-ready, provided you apply the claim-level checks defined elsewhere before acting.

Under the binary rule stated above, any missing criterion—including C2—means the report is a skip for health use. A report with C1 and C3 intact but another gap may serve only as background for a clinician conversation; it is not a Trust report.

A Skip report fails the minimum bar. Any report that scores 0 on C1 or C3, or that falls below 3/5 overall, should be set aside regardless of how polished the presentation appears. Without analytical validity or actionability, the report cannot reliably inform what is true about your biology or what you should do next, making further interpretation a poor use of time and attention.

When comparing options, prioritize completeness over volume. A 5/5 report with a named guideline action beats a 4/5 report with a large marker count because the missing criterion is clinical utility, not data volume. More markers do not compensate for a gap that prevents a claim from translating into a trustworthy, actionable decision.

Costs and Numbers to Normalize

The only defensible comparison between two personal-genomics reports is a 12-month all-in total, built in four separate cells: the one-time report fee, the monthly subscription multiplied by 12, the raw-data export fee, and the re-test fee. Put each in its own row and sum them. A monthly sticker price and a one-time sticker price are different units; placing them side by side is the most common way a buyer underestimates a subscription report.

The formula is 12-month total = one-time fee + (monthly fee × 12) + export fee + re-test fee. If a company quotes only a monthly price, the 12-month figure is 12 times that monthly amount plus any fees. If it quotes only a one-time price, the 12-month figure is that amount plus fees. Same unit, same window — then, and only then, compare.

If raw-data export or deletion terms are not stated on the pricing page or in the terms of service, mark the cost as unknown and treat the report as a skip for health claims. An unstated term is not a blank to fill with an assumption; it is a failed C5. Under the binary rule, unknown C5 cannot be scored 1, and a report missing any criterion is a skip regardless of how the other four look.

Count claims, not companies. A 50-claim report is not 50 trusted claims; it is 50 separate rows in the checklist, and each row needs its own score on C1 through C5. The same company can ship one fully scored claim and one zero-scored claim in the same document, so any company-level average is a number with no meaning.

Export and deletion fees deserve their own line items because they are the charges most often buried outside the marketing page. One report may bundle raw-data export into the subscription, another may charge per download, and a third may charge for deletion on top. Each is a distinct cell in the 12-month total, and each unstated one converts the whole total to unknown. Read the terms of service, not the pricing banner — the banner advertises the subscription; the terms page carries the fees.

For any cost cell that cannot be filled from a primary source, follow the rule above: mark it unknown and do not score the report for health claims.

What the Reports Cannot Prove

This section alone lists edge cases where a full score still cannot establish clinical utility. A perfect result means the report passed the stated evidence, ancestry, action, disclosure, and export checks; it does not show that using the result changes a health outcome for you. It is a gate, not a guarantee.

A full score cannot prove that a statistical association changes outcomes in your age, sex, medication, or family-history context. Check whether the report names the population studied and the outcome measured; if it only gives a relative risk or score without that context, treat the claim as unproven for your situation.

A research-use-only report can have C1 and C2 but lacks C3. That means the association and ancestry match may be documented while no guideline-backed action is supplied, so the report should not drive a health decision.

Apply these limits after scoring, not before: a monogenic claim with a guideline action can still be trustworthy, a polygenic claim without ancestry validation fails C2, and a raw file alone is a skip for health. If the report cannot name the studied population and outcome, or if it is research-use-only, the health claim remains unestablished for you even when every criterion is met.

Clinical utility is a separate question from validity. Ask for the study design, endpoint, and comparison group behind any claim that a result should change screening, prevention, or treatment; without those details, the score is a filter, not proof.

Scoring 5 Criteria

Applying the five binary criteria to a hypothetical 2026 personal-genomics report with five claims produces 25 cells to score. Before reading the company’s summary, record each checkpoint as 0 or 1 based only on the underlying documentation for that claim. This prevents marketing language from filling gaps in the evidence or the recommended next step.

The checkpoints make the scoring concrete. Claim 1 earns a 1 for C2 because it cites a PMID and documents an ancestry match, and it earns a 1 for C3 because it pairs the finding with a guideline-backed action. Claim 2 also cites a PMID, but it names no ancestry group for the supporting evidence, so C2 is recorded as 0. Claim 4 documents an ancestry match but provides no guideline-backed action, so C3 is recorded as 0. Each cell is scored independently; a strong citation does not compensate for a missing ancestry match or a missing action.

In this hypothetical report, Claim 1 passes 5/5, Claim 2 fails C2, Claim 3 fails C2, Claim 4 fails C3, and Claim 5 passes 5/5. The observed result is that 2 of 5 claims are trusted. Treating the report as a single product would obscure that three claims fall short on different criteria, even when they share the same total.

Use the same checklist for every report you evaluate: list each claim as a row, score C1 through C5 as 0 or 1, and calculate the total only after every cell is filled. Completing the checklist claim by claim keeps the review auditable and makes it clear exactly which evidence or action is missing before any decision is made.

If-Then Rules for Trust or Skip

Convert the five binary criteria into a sequence of if-then actions rather than a single score. Read them in order, and let the first zero determine the report's highest permissible use. This keeps a strong result in one area from masking a failure in another. A practical check is to write the criteria in order and mark the first zero before reading any trait narrative.

For C1, apply the first-zero rule already stated: a zero on analytical validity makes the report a skip for health use no matter how the other criteria score. The question to ask support is whether the named analytical-validity study covers the exact variant and platform.

For C2, use the ancestry-match rule above: if the evidence’s ancestry group is not stated or not matched to the buyer, the claim fails and cannot support a health decision. Ask which ancestry group was studied; a broad continental label alone does not establish a match.

If C3 is 0, skip the report for clinical decisions and use it only as background information. A result without a guideline-backed action can inform curiosity or family discussion, but it should not drive screening, medication, or lifestyle change. Ask what guideline names the action and whether it applies to the buyer's age, sex, and risk profile; if no guideline is named, the zero stands.

If C4 is 0, leave the claim unranked: without disclosed effect size and penetrance, you cannot weigh it against other risks or judge whether follow-up is proportionate. If C5 is 0, treat the report as non-portable: without raw-data export, you cannot seek an independent second opinion or reanalyze the file later. For C4, ask for absolute risk, relative risk, and penetrance; for C5, ask for file format and whether deletion is possible after export.

Apply the rules claim by claim, not only to the whole report, and record the first failed criterion. That record is more useful than a total because it identifies whether the problem is the assay, the population match, the action, the magnitude, or portability. Use that recorded failure as the single question for customer support or a clinician, rather than asking whether the report is "good."

Frequently Asked Questions

If a report scores 4 out of 5, should it be treated as nearly trustworthy?

A 4/5 report is not "almost trustworthy"; it is a skip.

What score is required for a report to be trustworthy?

The trust cutoff is 5/5 — every criterion at 1.

What type of gate is the 5-point validity score?

A 5-point validity score is a pass-fail gate, not a percentage.

What must every health or trait claim name to be trustworthy?

Every health or trait claim must name an analytical-validity study, a clinical-validity study matched to the buyer’s ancestry group, and a guideline-backed action.

Which criterion requires ancestry-matched clinical validity?

C2 requires ancestry-matched clinical validity.

What does C3 require for each health or trait claim?

C3 requires a guideline-backed action, and each health or trait claim must be tied to a specific action supported by established guidelines.

Quick answers

Also worth reading: Understanding Psychometric Test Struggles for Enhanced Performance: Understanding Psychometric Test Struggles for · Essential Learning Paths for Psychometric Scale Design: Essential Learning Paths for Psychometric · Master Your Psychometric Test Hundreds Of Free Practice Resources: Master Your Psychometric Test Hundreds